TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Wednesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD opened at $1.11 on Wednesday. The stock’s 50-day moving average price is $1.30 and its 200-day moving average price is $1.56. TherapeuticsMD has a 52 week low of $0.70 and a 52 week high of $2.75.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP grew its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.